Review





Similar Products

rac1 2 3 antibody g 2  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology rac1 2 3 antibody g 2
Rac1 2 3 Antibody G 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac+1%2F2%2F3+Antibody/pmc12968423-309-34-38
Average 93 stars, based on 1 article reviews
rac1 2 3 antibody g 2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
rac1 2 3 g lisa activation assays  (Cytoskeleton Inc)
93
Cytoskeleton Inc rac1 2 3 g lisa activation assays
Rac1 2 3 G Lisa Activation Assays, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac1%2C2%2C3+G-LISA+GTPase+Activation+Assay/pmc13018806-58-2-24
Average 93 stars, based on 1 article reviews
rac1 2 3 g lisa activation assays - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
rac1  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology rac1
Rac1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac+1%2F2%2F3+Antibody/pm41901315-177-48-50
Average 93 stars, based on 1 article reviews
rac1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
anti rac1 gtp  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti rac1 gtp
Anti Rac1 Gtp, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac+1%2F2%2F3+Antibody/pmc12822358-244-10-12
Average 93 stars, based on 1 article reviews
anti rac1 gtp - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
rac2 inhibition assays  (MedChemExpress)
94
MedChemExpress rac2 inhibition assays
Ubiquitination‐mediated degradation of <t>RAC2</t> impairs macrophage differentiation in the Sirt5 ‐deficient ovarian environment. (A) Identification of SIRT5‐interacting proteins in M‐CSF‐stimulated monocytes by immunoprecipitation (IP) followed by mass spectrometry (MS), showing the number of peptides detected for interacting proteins. (B) Reciprocal co‐IP in RAW264.7 cells co‐expressing HA‐tagged RAC2 and Myc‐tagged SIRT5 showing their direct interaction. (C) Endogenous interaction between SIRT5 and RAC2 confirmed by reciprocal co‐IP in mouse ovarian tissues. (D) SIRT5 deficiency increases RAC2 succinylation, as shown by elevated succinylation levels in SIRT5‐knockdown RAW264.7 cells (left) and Sirt5 −/− monocytes (right). (E) RAC2 was immunoprecipitated from mouse ovarian lysates, followed by a western blot to assess lysine succinylation. (F) Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls. (G) Co‐IF staining for RAC2 (red) and F4/80 (green) in ovarian sections reveals diminished RAC2 expression in F4/80⁺ macrophages from Sirt5 −/− mice compared to wild‐type controls. (H) RAC2 ubiquitination is elevated under SIRT5‐deficient conditions, as shown by increased ubiquitination in SIRT5‐knockdown or MC3482‐treated RAW264.7 cells. (I) Both ubiquitination and succinylation of RAC2 are elevated in monocytes from Sirt5 −/− mice compared with those from wild‐type controls. (J,K) Impaired monocyte‐to‐macrophage differentiation upon RAC2 inhibition. (J) qRT–PCR analysis shows reduced expression of macrophage markers ( Adgre1 , Fcgr1 , Cd68 ) in negatively selected monocytes following NSC23766 (RAC2 inhibitor) treatment ( n = 3 per group; one‐way ANOVA with Tukey's multiple comparisons test). Data are normalized to β‐actin and presented as Mean ± SD. ** p < 0.01; **** p < 0.0001. (K) IF staining for F4/80 (green) confirms impaired macrophage differentiation in the NSC23766‐treated group. Scale bar: 20 µm.
Rac2 Inhibition Assays, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/RAC1%2F2%2F3+Antibody/pmc12970288-345-1-22
Average 94 stars, based on 1 article reviews
rac2 inhibition assays - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
rac1 2 3  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc rac1 2 3
Ubiquitination‐mediated degradation of <t>RAC2</t> impairs macrophage differentiation in the Sirt5 ‐deficient ovarian environment. (A) Identification of SIRT5‐interacting proteins in M‐CSF‐stimulated monocytes by immunoprecipitation (IP) followed by mass spectrometry (MS), showing the number of peptides detected for interacting proteins. (B) Reciprocal co‐IP in RAW264.7 cells co‐expressing HA‐tagged RAC2 and Myc‐tagged SIRT5 showing their direct interaction. (C) Endogenous interaction between SIRT5 and RAC2 confirmed by reciprocal co‐IP in mouse ovarian tissues. (D) SIRT5 deficiency increases RAC2 succinylation, as shown by elevated succinylation levels in SIRT5‐knockdown RAW264.7 cells (left) and Sirt5 −/− monocytes (right). (E) RAC2 was immunoprecipitated from mouse ovarian lysates, followed by a western blot to assess lysine succinylation. (F) Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls. (G) Co‐IF staining for RAC2 (red) and F4/80 (green) in ovarian sections reveals diminished RAC2 expression in F4/80⁺ macrophages from Sirt5 −/− mice compared to wild‐type controls. (H) RAC2 ubiquitination is elevated under SIRT5‐deficient conditions, as shown by increased ubiquitination in SIRT5‐knockdown or MC3482‐treated RAW264.7 cells. (I) Both ubiquitination and succinylation of RAC2 are elevated in monocytes from Sirt5 −/− mice compared with those from wild‐type controls. (J,K) Impaired monocyte‐to‐macrophage differentiation upon RAC2 inhibition. (J) qRT–PCR analysis shows reduced expression of macrophage markers ( Adgre1 , Fcgr1 , Cd68 ) in negatively selected monocytes following NSC23766 (RAC2 inhibitor) treatment ( n = 3 per group; one‐way ANOVA with Tukey's multiple comparisons test). Data are normalized to β‐actin and presented as Mean ± SD. ** p < 0.01; **** p < 0.0001. (K) IF staining for F4/80 (green) confirms impaired macrophage differentiation in the NSC23766‐treated group. Scale bar: 20 µm.
Rac1 2 3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac1%2F2%2F3+Antibody/pmc12823269-291-33-37
Average 95 stars, based on 1 article reviews
rac1 2 3 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
rac1  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc rac1
Ubiquitination‐mediated degradation of <t>RAC2</t> impairs macrophage differentiation in the Sirt5 ‐deficient ovarian environment. (A) Identification of SIRT5‐interacting proteins in M‐CSF‐stimulated monocytes by immunoprecipitation (IP) followed by mass spectrometry (MS), showing the number of peptides detected for interacting proteins. (B) Reciprocal co‐IP in RAW264.7 cells co‐expressing HA‐tagged RAC2 and Myc‐tagged SIRT5 showing their direct interaction. (C) Endogenous interaction between SIRT5 and RAC2 confirmed by reciprocal co‐IP in mouse ovarian tissues. (D) SIRT5 deficiency increases RAC2 succinylation, as shown by elevated succinylation levels in SIRT5‐knockdown RAW264.7 cells (left) and Sirt5 −/− monocytes (right). (E) RAC2 was immunoprecipitated from mouse ovarian lysates, followed by a western blot to assess lysine succinylation. (F) Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls. (G) Co‐IF staining for RAC2 (red) and F4/80 (green) in ovarian sections reveals diminished RAC2 expression in F4/80⁺ macrophages from Sirt5 −/− mice compared to wild‐type controls. (H) RAC2 ubiquitination is elevated under SIRT5‐deficient conditions, as shown by increased ubiquitination in SIRT5‐knockdown or MC3482‐treated RAW264.7 cells. (I) Both ubiquitination and succinylation of RAC2 are elevated in monocytes from Sirt5 −/− mice compared with those from wild‐type controls. (J,K) Impaired monocyte‐to‐macrophage differentiation upon RAC2 inhibition. (J) qRT–PCR analysis shows reduced expression of macrophage markers ( Adgre1 , Fcgr1 , Cd68 ) in negatively selected monocytes following NSC23766 (RAC2 inhibitor) treatment ( n = 3 per group; one‐way ANOVA with Tukey's multiple comparisons test). Data are normalized to β‐actin and presented as Mean ± SD. ** p < 0.01; **** p < 0.0001. (K) IF staining for F4/80 (green) confirms impaired macrophage differentiation in the NSC23766‐treated group. Scale bar: 20 µm.
Rac1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rac1+2+3/Rac1%2F2%2F3+Antibody/pm41359424-258-33-38
Average 95 stars, based on 1 article reviews
rac1 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


Ubiquitination‐mediated degradation of RAC2 impairs macrophage differentiation in the Sirt5 ‐deficient ovarian environment. (A) Identification of SIRT5‐interacting proteins in M‐CSF‐stimulated monocytes by immunoprecipitation (IP) followed by mass spectrometry (MS), showing the number of peptides detected for interacting proteins. (B) Reciprocal co‐IP in RAW264.7 cells co‐expressing HA‐tagged RAC2 and Myc‐tagged SIRT5 showing their direct interaction. (C) Endogenous interaction between SIRT5 and RAC2 confirmed by reciprocal co‐IP in mouse ovarian tissues. (D) SIRT5 deficiency increases RAC2 succinylation, as shown by elevated succinylation levels in SIRT5‐knockdown RAW264.7 cells (left) and Sirt5 −/− monocytes (right). (E) RAC2 was immunoprecipitated from mouse ovarian lysates, followed by a western blot to assess lysine succinylation. (F) Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls. (G) Co‐IF staining for RAC2 (red) and F4/80 (green) in ovarian sections reveals diminished RAC2 expression in F4/80⁺ macrophages from Sirt5 −/− mice compared to wild‐type controls. (H) RAC2 ubiquitination is elevated under SIRT5‐deficient conditions, as shown by increased ubiquitination in SIRT5‐knockdown or MC3482‐treated RAW264.7 cells. (I) Both ubiquitination and succinylation of RAC2 are elevated in monocytes from Sirt5 −/− mice compared with those from wild‐type controls. (J,K) Impaired monocyte‐to‐macrophage differentiation upon RAC2 inhibition. (J) qRT–PCR analysis shows reduced expression of macrophage markers ( Adgre1 , Fcgr1 , Cd68 ) in negatively selected monocytes following NSC23766 (RAC2 inhibitor) treatment ( n = 3 per group; one‐way ANOVA with Tukey's multiple comparisons test). Data are normalized to β‐actin and presented as Mean ± SD. ** p < 0.01; **** p < 0.0001. (K) IF staining for F4/80 (green) confirms impaired macrophage differentiation in the NSC23766‐treated group. Scale bar: 20 µm.

Journal: Advanced Science

Article Title: SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

doi: 10.1002/advs.202518417

Figure Lengend Snippet: Ubiquitination‐mediated degradation of RAC2 impairs macrophage differentiation in the Sirt5 ‐deficient ovarian environment. (A) Identification of SIRT5‐interacting proteins in M‐CSF‐stimulated monocytes by immunoprecipitation (IP) followed by mass spectrometry (MS), showing the number of peptides detected for interacting proteins. (B) Reciprocal co‐IP in RAW264.7 cells co‐expressing HA‐tagged RAC2 and Myc‐tagged SIRT5 showing their direct interaction. (C) Endogenous interaction between SIRT5 and RAC2 confirmed by reciprocal co‐IP in mouse ovarian tissues. (D) SIRT5 deficiency increases RAC2 succinylation, as shown by elevated succinylation levels in SIRT5‐knockdown RAW264.7 cells (left) and Sirt5 −/− monocytes (right). (E) RAC2 was immunoprecipitated from mouse ovarian lysates, followed by a western blot to assess lysine succinylation. (F) Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls. (G) Co‐IF staining for RAC2 (red) and F4/80 (green) in ovarian sections reveals diminished RAC2 expression in F4/80⁺ macrophages from Sirt5 −/− mice compared to wild‐type controls. (H) RAC2 ubiquitination is elevated under SIRT5‐deficient conditions, as shown by increased ubiquitination in SIRT5‐knockdown or MC3482‐treated RAW264.7 cells. (I) Both ubiquitination and succinylation of RAC2 are elevated in monocytes from Sirt5 −/− mice compared with those from wild‐type controls. (J,K) Impaired monocyte‐to‐macrophage differentiation upon RAC2 inhibition. (J) qRT–PCR analysis shows reduced expression of macrophage markers ( Adgre1 , Fcgr1 , Cd68 ) in negatively selected monocytes following NSC23766 (RAC2 inhibitor) treatment ( n = 3 per group; one‐way ANOVA with Tukey's multiple comparisons test). Data are normalized to β‐actin and presented as Mean ± SD. ** p < 0.01; **** p < 0.0001. (K) IF staining for F4/80 (green) confirms impaired macrophage differentiation in the NSC23766‐treated group. Scale bar: 20 µm.

Article Snippet: For RAC2 inhibition assays, monocytes were treated from day 0 of differentiation with either DMSO (vehicle control) or 100 μ m NSC23766 (MedChemExpress, China) dissolved in DMSO.

Techniques: Ubiquitin Proteomics, Immunoprecipitation, Mass Spectrometry, Co-Immunoprecipitation Assay, Expressing, Knockdown, Western Blot, Inhibition, Staining, Quantitative RT-PCR